{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:58:31Z","timestamp":1787021911805,"version":"build-2736575974"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0086401","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T16:31:20Z","timestamp":1390840280000},"page":"e86401","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improved Diagnosis of the Transition to JAK2V617F Homozygosity: The Key Feature for Predicting the Evolution of Myeloproliferative Neoplasms"],"prefix":"10.1371","volume":"9","author":[{"given":"Mariana Selena","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Daniel","family":"De Brasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gargallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stanganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Beatriz","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutations of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"EJ Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain of function mutation of JAK2 in Myeloproliferative Disorders","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Acting mutation in the tyrosine kinase JAK2 in polycithemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis","volume":"7","author":"RL Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref5","first-page":"22788","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol","volume":"280","author":"R Zhao","year":"2005","journal-title":"Chem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"JAK2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"E Parganas","year":"1998","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Constantinescu S (2005) A unique activating mutation in JAK2 (V617) is at the Origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 195\u2013200.","DOI":"10.1182\/asheducation-2005.1.195"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"RL Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"MPD Research Consortium: Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden","volume":"21","author":"AM Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"A Carobbio","year":"2009","journal-title":"Exp Hematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2008.001271","article-title":"Clinical relevance of JAK2 (V617F) mutant allele burden","volume":"94","author":"F Passamonti","year":"2009","journal-title":"Haematologica"},{"key":"ref12","first-page":"387","article-title":"Polycythemia vera and its molecular basis: An update. Best Pract Res Clin Haematol","volume":"19","author":"G Chen","year":"2006"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"A Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.leu.2404209","article-title":"A quantitative assay for JAK2<sup>V617F<\/sup> mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis","volume":"20","author":"AM Vannucchi","year":"2006","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"AV Jones","year":"2005","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.humpath.2006.05.006","article-title":"Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay. A retrospective study with pathologic correlations","volume":"37","author":"M Bousquet","year":"2006","journal-title":"Hum Pathol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMc051878","article-title":"<italic>JAK2<\/italic> Mutations in Myeloproliferative Disorders","volume":"353","author":"A Tefferi","year":"2005","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The Myeloproliferative Disorders","volume":"355","author":"PJ Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"JW Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","article-title":"Concordance of assays designed for the quantification of JAK2V617F: a multicenter study","volume":"94","author":"E Lippert","year":"2009","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","article-title":"Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&amp;MPNr-EuroNet (COST action BM0902) study","volume":"27","author":"J Jovanovic","year":"2013","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.leu.2404081","article-title":"JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders","volume":"20","author":"H Quentmeier","year":"2006","journal-title":"Leukemia"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"E Lippert","year":"2006","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2V617F to wild type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"R Tiedt","year":"2008","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0086401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:43:11Z","timestamp":1588984991000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0086401"}},"subtitle":[],"editor":[{"given":"Connie J.","family":"Eaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0086401","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}